Who are Aer Therapeutics's investors?

Aer Therapeutics's investors include Hatteras Venture Partners, OrbiMed, Canaan Partners, Pappas Capital.

How much funding has Aer Therapeutics raised?

Aer Therapeutics has disclosed $23.9M raised across 3 rounds.

Where is Aer Therapeutics headquartered?

Aer Therapeutics is headquartered in Raleigh, US.

Aer Therapeutics

Raleigh, US · Founded 2014 · 10 employees on LinkedIn · 4 known investors

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma. The company focuses on respiratory care for patients with these conditions.

Biotech Healthtech Medical Devices

Founders & leadership

Thomas MathersinExecutive Chairman of the Board of Directors

James ShafferExecutive

John FahyinFounder and Chief Clinical Consultant

Board

Christy Shaffer inBoard directorGeneral Partner at Hatteras Venture Partners

Rishi GuptaBoard director

Tim Shannon in 𝕏Board directorGeneral Partner at Canaan Partners

Evan Caplan inBoard directorInvestor at OrbiMed

Investors · 4

Hatteras Venture Partners✓ verifiedResearch Triangle · $500K – $4M

OrbiMed✓ verifiedNew York · $1M – $75M

Canaan PartnersStamford · $500K – $20M

Pappas CapitalDurham

Reported raises · per SEC filings

Form D private placements

$23.9M disclosed across 3 rounds · 2022–2026

▶$3MraisedAug 2026 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Thomas MathersExecutive Officer, Director
John FahyDirector
Evan CaplanDirector
Tim ShannonDirector
Christy ShafferDirector

Offering amount: $3M
Amount sold: $3M
First sale: Aug 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5MraisedFeb 2025 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

CHRISTY SHAFFERDirector
THOMAS MATHERSExecutive Officer, Director
RISHI GUPTADirector
JOHN FAHYDirector
TIM SHANNONDirector

Offering amount: $5M
Amount sold: $5M
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$15.9MraisedDec 2022 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Tim ShannonDirector
Christy ShafferDirector
Rishi GuptaDirector
James ShafferExecutive Officer, Director
John FahyDirector

Offering amount: $36.9M
Amount sold: $15.9M
First sale: Dec 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Investors - AER Therapeuticsaertherapeutics.com · May 2025

Aer Therapeutics raises $36M for COPD treatment - Triangle Business Journalbizjournals.com · Apr 2023

Aer Therapeutics Raises $36M in Series A Fundingfinsmes.com · Apr 2023

Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseasesprnewswire.com · Apr 2023

Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases - AER Therapeuticsaertherapeutics.com · Apr 2023

Frequently asked questions

What does Aer Therapeutics do?: Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma. The company focuses on respiratory care for patients with these conditions.
Who are Aer Therapeutics's investors?: Aer Therapeutics's investors include Hatteras Venture Partners, OrbiMed, Canaan Partners, Pappas Capital.
How much funding has Aer Therapeutics raised?: Aer Therapeutics has disclosed $23.9M raised across 3 rounds.
Where is Aer Therapeutics headquartered?: Aer Therapeutics is headquartered in Raleigh, US.